Abstract
Induced pluripotent stem cells (iPSCs) generated from patients are a valuable tool for disease modelling, drug screening, and studying the functions of cell/tissue-specific genes. However, for this research, isogenic iPSC lines are important for comparison of phenotypes in the wild type and mutant differentiated cells generated from the iPSCs. The advent of gene editing technologies to correct or generate mutations helps in the generation of isogenic iPSC lines with the same genetic background. Due to the ease of programming, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-Cas9-based gene editing tools have gained pace in gene manipulation studies, including investigating complex diseases like cancer. An iPSC line with drug inducible Cas9 expression from the Adeno-Associated Virus Integration Site 1 (AAVS1) safe harbor locus offers a controllable expression of Cas9 with robust gene editing. Here, we describe a stepwise protocol for the generation and characterization of such an iPSC line (AAVS1-PDi-Cas9 iPSC) with a doxycycline (dox)-inducible Cas9 expression cassette from the AAVS1 safe harbor site and efficient editing of target genes with lentiviral vectors expressing gRNAs. This approach with a tunable Cas9 expression that allows investigating gene functions in iPSCs or in the differentiated cells can serve as a versatile tool in disease modelling studies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Georgomanoli M, Papapetrou EP (2019) Modeling blood diseases with human induced pluripotent stem cells. Dis Model Mech 12:dmm039321
Kim HS, Bernitz JM, Lee D-F et al (2014) Genomic editing tools to model human diseases with isogenic pluripotent stem cells. Stem Cells Dev 23:2673–2686
Bassett AR (2017) Editing the genome of hiPSC with CRISPR/Cas9: disease models. Mamm Genome 28:348–364
González F, Zhu Z, Shi Z-D et al (2014) An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. Cell Stem Cell 15:215–226
Zhu Z, González F, Huangfu D (2014) The iCRISPR platform for rapid genome editing in human pluripotent stem cells. Methods Enzymol 546:215–250
Dow LE, Fisher J, O’Rourke KP et al (2015) Inducible in vivo genome editing with CRISPR-Cas9. Nat Biotechnol 33:390–394
Mandegar MA, Huebsch N, Frolov EB et al (2016) CRISPR interference efficiently induces specific and reversible gene silencing in human iPSCs. Cell Stem Cell 18:541–553
Ihry RJ, Worringer KA, Salick MR et al (2018) p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells. Nat Med 24:939–946
Enache OM, Rendo V, Abdusamad M et al (2020) Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nat Genet 52:662–668
Ran FA, Hsu PD, Wright J et al (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8:2281–2308
Steyer B, Carlson-Stevermer J, Angenent-Mari N et al (2016) High content analysis platform for optimization of lipid mediated CRISPR-Cas9 delivery strategies in human cells. Acta Biomater 34:143–158
Ringer KP, Roth MG, Garey MS et al (2018) Comparative analysis of lipid-mediated CRISPR-Cas9 genome editing techniques: simplified Cas9-mediated genome editing. Cell Biol Int 42:849–858
Sanjana NE, Shalem O, Zhang F (2014) Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 11:783–784
Cao J, Wu L, Zhang S-M et al (2016) An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting. Nucleic Acids Res 44:e149
Xia X, Zhang Y, Zieth CR et al (2007) Transgenes delivered by lentiviral vector are suppressed in human embryonic stem cells in a promoter-dependent manner. Stem Cells Dev 16:167–176
Suzuki Y, Suzuki Y (2011) Gene regulatable lentiviral vector system. In: Xu K (ed) Viral gene therapy. InTech, Rijeka, pp 285–309
Smith JR, Maguire S, Davis LA et al (2008) Robust, persistent transgene expression in human embryonic stem cells is achieved with AAVS1-targeted integration. Stem Cells 26:496–504
Luo Y, Liu C, Cerbini T et al (2014) Stable enhanced green fluorescent protein expression after differentiation and transplantation of reporter human induced pluripotent stem cells generated by AAVS1 transcription activator-like effector nucleases. Stem Cells Transl Med 3:821–835
Heckl D, Kowalczyk MS, Yudovich D et al (2014) Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol 32:941–946
Manian KV, Bharathan SP, Maddali M et al (2018) Generation of an integration-free iPSC line (CSCRi005-A) from erythroid progenitor cells of a healthy Indian male individual. Stem Cell Res 29:148–151
Acknowledgments
This research work is funded by Department of Biotechnology, Government of India (grant number BT/PR17316/MED/31/326/2015) and DBT/Wellcome Trust India Alliance Fellowship [grant number IA/S/17/1/503118] awarded to SRV.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Thamodaran, V., Rani, S., Velayudhan, S.R. (2021). Gene Editing in Human Induced Pluripotent Stem Cells Using Doxycycline-Inducible CRISPR-Cas9 System. In: Nagy, A., Turksen, K. (eds) Induced Pluripotent Stem (iPS) Cells. Methods in Molecular Biology, vol 2454. Humana, New York, NY. https://doi.org/10.1007/7651_2021_348
Download citation
DOI: https://doi.org/10.1007/7651_2021_348
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2118-9
Online ISBN: 978-1-0716-2119-6
eBook Packages: Springer Protocols